Option chain shows key data for Imunon's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Imunon.

Imunon (NASDAQ:IMNN) Stock, Option Chain

IMUNON INC

Imunon

Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).

vaccine-4892059

News

IMNN

Imunon shares are trading lower by 61% during Wednesday&#39;s session. The company announced a $10 million registered direct offering.

Why Imunon (IMNN) Stock Is Down 60% Today

Wall Street bull

Earnings

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

FGEN

FVRR

MSFT

PEPG

POWL

Nasdaq Surges Over 3%; Powell Industries Shares Spike Higher

Wall Street, US stocks

NCNC

NUZE

PMEC

Dow Jumps Over 200 Points; Kraft Heinz Shares Gain After Q2 Earnings

Imunon Inc

Press Releases

IMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual Meeting

IMUNON Announces Results from its End-of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer

IMUNON Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 OVATION 2 Study of IMNN-001

IMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer

IMUNON Appoints Douglas V. Faller, M.D., Ph.D., as Chief Medical Officer

IMUNON Announces Translational Data from Phase 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer

IMUNON to Hold 2024 Financial Results and Business Update Conference Call on Thursday, February 27, 2025

IMUNON Announces New Immunogenicity Data from Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of COVID-19

IMUNON Reports 2024 Financial Results and Provides Business Update Highlighting Significant Progress Towards the Initiation of a Pivotal Phase 3 Study

IMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

ABVC BioPharma

Aprea Therapeutics

BioCardia

BioLineRx Ltd. - American Depositary Shares

BioLine Rx

Bolt Biotherapeutics, Inc. - Common Stock

Bolt Biotherapeutics

BioRestorative Therapies, Inc. - Common Stock

BioRestorative Therapies

Carisma Therapeutics, Inc. - Common Stock

CARISMA Therapeutics

Dogwood Therapeutics, Inc. - Common Stock

Dogwood Therapeutics

Eterna Therapeutics

GlycoMimetics

Geovax Labs

HCW Biologics

HOOKIPA Pharma

Kairos Pharma

Leap Therapeutics

Moleculin Biotech

MEI Pharma

Marker Therapeutics

MetaVia

Minerva Neurosciences, Inc - Common Stock

Minerva Neurosciences

NextCure

BiomX

SAB Biotherapeutics

Spruce Biosciences

Synlogic

HC Wainwright & Co.

D. Boral Capital

EF Hutton

Alliance Global Partners

Comments

Imunon

Imunon (IMNN) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga